AT-1413
AT-1413 is a monoclonal antibody targeting CD43s that recognizes a unique sialylated CD43 epitope spanning amino acid residues 133-165. AT1413 induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in AML cells, with EC50 values of 1.1 nM and 12.4 nM, respectively. AT-1413 binds to a variety of cancer cells, shows weak binding to non-malignant myeloid cells and endothelial cells, and does not bind to healthy lymphoid cells or normal non-hematopoietic cells. AT1413 clears CD43s-expressing leukemic blasts in vivo without affecting non-malignant myeloid cells. AT-1413 can be used in research related to acute myeloid leukemia, myelodysplastic syndrome, melanoma, and breast cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
CD43
In Vitro
AT-1413 (0.5-1.25 µg/mL) binds to CD43s on melanoma cell lines, some breast cancer cell lines, myeloid leukemia cell lines, as well as 86% of short-term cultured melanoma samples, as detected by flow cytometry[1].
AT-1413 (10 µg/mL) binds to CD43s in 72% of melanoma tissue samples, but does not bind to adjacent healthy skin cells, as detected by immunohistochemistry[1].
AT-1413 (3 h) recognizes the sialylated epitope of CD43 (CD43s) on the 136.2 and A375 melanoma cell lines[1].
AT-1413 (1-25 µg/mL; 4 h) induces antibody-dependent cellular cytotoxicity against the A375, 136.2 and BLM melanoma cell lines, as well as the patient-derived melanoma samples MEL12.07, MEL06.07 and MEL99.08, in vitro[1].
AT1413 (0.001-20 μg/mL) potently induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in SH2-type AML cells in vitro, with EC50 values of 1.1 nM and 12.4 nM, respectively, but does not induce cytotoxicity in non-malignant HAEC, HUVEC or healthy granulocytes[2].
AT1413 (3 h) specifically binds to the unique sialylated epitope (CD43s) located between amino acid residues 133 and 165 of the CD43 protein, which is expressed in human THP-1 and Molm13 acute myeloid leukemia (AML) cell lines as well as the mouse WEHI-3b AML cell line[2].
AT1413 specifically binds to CD43s on the surface of AML/MDS blasts, human AML cell lines, and mouse WEHI-3b AML cells, while it shows weak binding to some non-malignant myeloid cells and endothelial cells, and no binding to healthy lymphoid cells or non-hematopoietic cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
AT-1413 (15 mg/kg; i.v.; biweekly) potently eliminates human AML blasts in humanized NSG mice without affecting nonmalignant human myeloid cells[2].
AT-1413 (15 mg/kg; i.v.; biweekly) reduces AML tumor growth in nonhumanized NSG mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NSG mice (NOD.Cg- PrkdcscidIl2rgtm1Wjl/SzJ) (female newborn, human immune system reconstituted, sublethally irradiated, inoculated with human AML cell line SH2 cells)[2]
-
Dosage:15 mg/kg
-
Administration:i.v.; biweekly; starting day 19 after AML cell inoculation
-
Result:Strongly inhibited AML tumor growth via whole-body bioluminescence measurement.
Eliminated AML infiltration in bone, liver, gut, lung, and spleen.
Maintained similar proportions of nonmalignant human CD45+ cells (including T cells, B cells, NK cells, and granulocytes) compared to control antibody-treated mice.
Caused only transient reduced food intake and weight loss after the first injection, with no other significant adverse effects.
-
Animal Model:NSG mice (NOD.Cg- PrkdcscidIl2rgtm1Wjl/SzJ) (nonhumanized, inoculated with luciferase-labeled human AML cell line SH2 cells)[2]
-
Dosage:15 mg/kg
-
Administration:i.v.; biweekly
-
Result:Demonstrated efficacy against luciferase-labeled SH2 AML cells.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
신청
ELISA, FACS, Functional assay
Chemical Information
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[AT-1413]
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
순도&문서
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. de Jong G, et al. Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo. Cancer immunology, immunotherapy : CII. 2021 Jun;70(6):1569-1581. [Content Brief]
[2]. Gillissen MA, et al. Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in mice. Blood advances. 2017 Aug 22;1(19):1551-1564. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)